Genetic polymorphisms of CYP2D6, GSTM1, and GSTT1 genes and bladder cancer risk in North India

Cancer Genetics and Cytogenetics

Volumn 156, Issue 1, 2005, Pages 68-73

  Sobti, R C ^a   Al Badran, A I ^a   Sharma, S ^a   Sharma, S K ^b   Krishan, A ^c   Mohan, H ^d  

^a PANJAB UNIVERSITY   (India)

^b POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^d GOVERNMENT MEDICAL COLLEGE AND HOSPITAL   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2D6; GLUTATHIONE TRANSFERASE; GLUTATHIONE TRANSFERASE M1; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER RISK; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DNA POLYMORPHISM; FEMALE; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE; HUMAN; HUMAN TISSUE; INDIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SMOKING;

AGED; CYTOCHROME P-450 CYP2D6; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GLUTATHIONE TRANSFERASE; HUMANS; INDIA; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; SMOKING; URINARY BLADDER NEOPLASMS;

EID: 10044240625     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cancergencyto.2004.04.001     Document Type: Article

References (51)

1. S.H. Landis, T. Murray, S. Bolden, and P.A. Wingo Cancer statistics CA Cancer J Clin 49 1999 1
2. K.N. Qureshi, T.R. Griffiths, M.C. Robinson, C. March, J.T. Roberts, R.R. Hall, J. Lunec, and D.E. Neal TP53 accumulation predicts improved survival in patients resistant to systematic cisplatin based chemotherapy for muscle-invasive bladder cancer Clin Cancer Res 8 1999 3500 3507
3. S.J. Lee, S.H. Cho, S.K. Park, S.W. Kim, M.S. Park, H.Y. Choi, J.Y. Choi, S.Y. Lee, H.J. Im, J.Y. Kim, K.J. Yoon, H. Choi, S.G. Shin, T.W. Park, N. Rothman, A. Hirvonen, and D. Kang Combined effect of glutathione S-transferase M1 and T1 genotypes on bladder cancer risk Cancer Lett 177 2002 173 179
4. H.B. Tongaonkar, A.V. Dalal, and J.N. Kulkarni Superficial bladder cancer. A 10 years experience Indian J Cancer 32 1995 141 148
5. U. Sen, R. Sankararayanan, S. Mandal, A.V. Ramana Kumar, D.M. Parkin, and M. Siddiqi Cancer patterns in eastern India: the first report of the Kolkata cancer registry Int J Cancer 100 2002 86 91
6. N. Fleshner, J. Garland, A. Moadel, H. Herr, J. Ostroff, R. Trambert, M. O'Sullivan, and P. Russo Influence of smoking status on the disease-related outcomes of patients with tobacco-associated superficial transitional cell carcinoma of the bladder cancer Cancer 86 1999 2337 2345
7. N. Fleshner, H. Heer, A. Stewart, G.P. Murphy, C. Mettlin, and H.R. Menck The National Cancer Data-Base report on bladder carcinoma Cancer 78 1996 1505 1513
8. H. Raunio, K. Husgafvel-Pursiainen, S. Anttila, E. Hietanen, A. Hirvonen, and O. Pelkonen Diagnosis of polymorphisms in carcinogen-activating and inactivating enzymes and cancer susceptibility: a review Gene 159 1995 113 121
9. A.J.C. Figueiredo, H.B. Coimbra, F.T. Sobral, J. Martins, A.J. Linhares-Furtado, and F.J. Regateiro Genetic polymorphisms of genes GSTMI and CYP2D6 and bladder cancer Braz J Urol 26 2000 250 255
10. M.E. Eichelbaum, and A.S. Gross The genetic polymorphisms of debrisoquine/sparteine metabolism-clinical aspects Pharmacol Ther 46 1990 377 394
11. A. Kaisary, P. Smith, C. Jaczq, C.B. McAllister, G.R. Wilkinson, W.A. Ray, and R.A. Branch Genetic predisposition to bladder cancer: ability to hydroxylate debrisoquine and mephenytoin as risk factors Cancer Res 47 1987 5488 5493
12. C.M. Fleming, A. Kaisary, G.R. Wilkinson, and R.A. Branch The ability to 4-hydroxylate debrisoquine is related to recurrence of bladder cancer Pharmacogenetics 2 1992 128 134
13. R.A. Persaad, C.M. Fleming, G.R. Wilkinson, P.J. Smith, and R.A. Branch Bladder cancer recurrence and its association with cytochrome P450 2D6 activity Prog Clin Biol Res 378 1992 19 27
14. J. Seidegrad, W.R. Vorachek, R.W. Pero, and W.R. Pearson Hereditary differences in the expression of the human glutathione transferase active on trans-stil-bene oxide are due to a gene deletion Proc Natl Acad Sci USA 85 1988 7293 7297
15. S. Pemble, K.R. Schroeder, S.R. Spencer, D.J. Meyer, E. Hallier, H.M. Bolt, B. Ketterer, and J.B. Taylor Human glutathione S-transferase (GSTTI): cDNA cloning and the characterization of a genetic polymorphism Biochem J 300 1994 271 276
16. H. Okkels, T. Sigsgaard, H. Wolf, and H. Autrup Glutathione S-transferase μ as risk factor in bladder tumors Pharmacogenetics 6 1996 251 256
17. J. Seidegard, R.W. Pero, M.M. Markowitz, G. Roush, D.G. Miller, and E.J. Beattie Isoenzyme(s) of glutathione transferase (class Mu) as a marker for the susceptibility to lung cancer: a follow up study Carcinogenesis 11 1990 33 36
18. D.A. Bell, J.A. Taylor, D.F. Paulson, C.N. Robertson, J.L. Mohler, and G.W. Lucier Genetic risk and carcinogen exposure: a common inherited defect of the carcinogen-metabolism gene glutathione S-transferase M1 (GSTM1) that increase susceptibility to bladder cancer J Natl Cancer Inst 85 1993 1159 1164
19. C.B. Ambrosone, J.L. Freudenheim, S. Graham, J.R. Marshall, J.E. Vena, and J.R. Brasure Cytochrome P4501A1 and glutathione S-transferase (M1) genetic polymorphisms and postmenopausal breast cancer risk Cancer Res 55 1995 3483 3485
20. K.T. Kelsey, S.E. Hankinson, G.A. Colditz, K. Springer, M. Garcia-Closas, and D. Spiegelman Glutathione S-transferase class mu deletion polymorphism and breast cancer: results from prevalent versus incident cases Cancer Epidemiol Biomarkers Prev 6 1997 511 515
21. J. Brockmoller, R. Kerb, N. Drakoulis, B. Staffeldt, and I. Roots Glutathione S-transferase M1 and its variants A and B as host factors of bladder cancer susceptibility: a case-control study Cancer Res 54 1994 4103 4111
22. W.A. Anwar, S.Z. Abdel-Rahman, R.A. El-Zein, H.M. Mostafa, and W.W. Au Genetic polymorphisms of GSTM1, CYP2E1 and CYP2D6 in Egyptian bladder Cancer patients Carcinogenesis 17 1996 1923 1929
23. J. Brockmoller, I. Cascorbi, R. Kerb, and I. Roots Combined analysis of inherited polymorphism in arylamine N-acetyltransferase 2, glutathione S-transferases M1 and T1, microsomal epoxide hydrolase, and cytochrome P450 enzymes as modulators of bladder cancer risk Cancer Res 56 1996 3915 3925
24. S. Zhong, A.H. Wyllie, D. Barnes, C.R. Wolf, and N.K. Spurr Relationship between the GSTM1 genetic polymorphism and susceptibility to bladder, breast and colon cancer Carcinogenesis 14 1993 1821 1824
25. H.J. Lin, C.Y. Han, D.A. Bernstein, W. Hsiao, B.K. Lin, and S. Hardy Ethnic distribution of the glutathione transferase Mu 1-1 (GSTM1) null genotype in 1473 individuals and application to bladder cancer susceptibility Carcinogenesis 15 1994 1077 1081
26. C. Steinhoff, K.H. Franke, K. Golka, R. Their, H.C. Romer, C. Rotzel, R. Ackermann, and W.A. Schulz Glutathione transferase isozyme genotypes in patients with prostate and bladder carcinoma Arch Toxicol 74 2000 521 526
27. P.P. Bringuier, M. McCredie, G. Sauter, M. Bilous, J. Stewart, M.J. Mihatsch, P. Kleihues, and H. Ohgaki Carcinomas of the renal pelvis associated with smoking and phenacetin abuse: p53 mutations and polymorphism of carcinogen-metabolising enzymes Int J Cancer 79 1998 531 536
28. T. Martone, P. Vineis, C. Malaveille, and B. Terracini Impact of polymorphisms in xeno (endo) biotic metabolism on pattern and frequency of p53 mutations in bladder cancer Mutat Res 462 2000 303 309
29. M. Peluso, L. Airoldi, C. Magagnotti, L. Fiorini, A. Munnia, A. Hautefeuille, C. Malaveille, and P. Vineis White blood cell DNA adduct and fruit and vegetable consumption in bladder cancer Carcinogenesis 21 2000 183 187
30. G.A. Toruner, C. Akyerli, A. Ucar, T. Aki, N. Atsu, H. Ozen, M. Tez, M. Cetinkaya, and T. Ozcelik Polymorphism of glutathione S-transferase genes (GSTM1, GSTP1 and GSTT1) and bladder cancer susceptibility in the Turkish population Arch Toxicol 75 2001 459 464
31. J. Sambrook, E.F. Fritsh, and T. Maniatis Molecular cloning, a laboratory manual 2nd ed. 1989 Cold Spring Harbor Laboratory Press Cold Spring Harbor, NY
32. C.A.D. Smith, A.C. Gough, P.N. Leigh, B.A. Summers, A.E. Harding, D.M. Maranganore, S.G. Sturnman, A.H.V. Schapira, S.A.C. William, N.K. Spurr, and C.R. Wolf Debrisoquine hydroxilase gene polymorphisms and susceptibility to Parkinson's disease Lancet 339 1992 1375 1377
33. M. Arand, R. Muhlbaur, J. Hengstler, E. Jager, J. Fuchs, L. Winkler, and F. Oesch A multiples polymerase chain reaction protocol for the simultaneous analysis of the glutathione-S-transferase GSTM1 and GSTT1 polymorphism Anal Biochem 236 1996 184 186
34. P.G. Shields, and C.C. Harris Molecular epidemiology and the genetics of environmental cancer JAMA 266 1991 681 687
35. S. Cholerton, C. Boustead, H. Taber, A. Arpanchi, and J.R. Idle CYP2D6 genotypes in cigarette smokers and non-tobacco users Pharmacogenetics 6 1996 261 263
36. N.K. Spurr, A.C. Cough, F.I. Chinegwundoh, and C.A.D. Smith Polymorphisms in drug-metabolizing enzymes as modifiers of cancer risk Clin Chem 41 1995 1864 1869
37. F.I. Chinegwundoh, and A.V. Kaisary Polymorphism and smoking in bladder carcinogenesis Br J Urol 77 1996 672 675
38. R.A. Branch, H.D. Chern, A. Adedoyin, M.R. Sparks, T.G. Lesnick, R. Persad, G.R. Wilkinson, A.J. Dickinson, G. Sibley, and P. Smith The procarcinogen hypothesis for bladder cancer, activities of individual drug metabolizing enzymes as risk factors Pharmacogenetics 5 1995 97 102
39. J. Seidegard, R.W. Pero, D.G. Miller, and E.J. Beatie A glutathione transferase in human leukocytes as a marker for the susceptibility to lung cancer Carcinogenesis 7 1986 751 753
40. S. Zhong, A.F. Howie, B. Ketterer, J. Taylor, J.D. Hayes, G.J. Beckett, G.C. Wathen, C.R. Wolf, and N.K. Spurr Glutathione-S-transferase mu locus: use of genotyping and phenotyping assays of assess association with lung cancer susceptibility Carcinogenesis 12 1991 1533 1537
41. T. Katoh, H. Inatomi, A. Nagaoka, and A. Sugita Cytochrome P4501A1 gene polymorphism and homozygous deletion of the glutathione S-transferase M1 gene in urothelial cancer patients Carcinogenesis 16 1995 655 657
42. Z.F. Zhang, A.S. Sarkis, C. Cardon Cardo, G. Dalbagi, J. Melamed, A. Aprikian, D. Pollack, J. Sheinfeld, H.W. Herr, and W.R. Fair Tobacco smoking occupation and p53 nuclear overexpression in early stage bladder cancer Cancer Epidemiol Biomarkers Prev 3 1994 19 24
43. J. Salagovic, I. Kalina, J. Stubna, V. Habalova, M. Hrivnak, L. Vlansky, A. Kohut, and E. Biros Genetic polymorphism of glutathione S-transferase M1 and T1 and risk factor in lung and bladder cancer Neoplasma 45 1998 312 317
44. N.A. Mungan, K.K. Aben, E. Beeks, E. Kampman, A. Bunschoten, M. Bussemakers, J.A. Witjes, and L.A. Kiemeney A germline homozygote deletion of the glutathione-S-transferase Mu1 gene predisposes to bladder cancer Urol Int 64 2000 134 138
45. S.J. Lee, D. Kang, S.H. Cho, S.U. Kim, M.S. Park, H.Y. Choi, and H. Choi Association of genetic polymorphism of glutathione S-transferase M1 and T1 and bladder cancer J Korean Cancer Assoc 31 1999 548 555
46. T. Hirayama, J.A.H. Waterhouse, and J.F. Fraumeni Cancer risk by site 1980 International Union Against Cancer Geneva, Switzerland:
47. B. Mannervik, P. Alin, C. Guthenberg, H. Jensson, M.K. Tahir, M. Warholm, and H. Jornall Identification of three classes of cytosolic glutathione transferase common to several mammalian species: Correlation between structural data and enzymatic properties Proc Natl Acad Sci USA 82 1985 7202 7206
48. H. Sies B. Ketterer Glutathione: mechanisms and significance. CRC critical reviews in biochemistry and molecular biology 1988 Academic Press London
49. T. Katoh, H. Inatomi, H. Kim, M. Yang, T. Matsumoto, and T. Kawamoto Effects of glutathione S-transferase (GST) M1 and GSST1 genotypes on urothelial cancer risk Cancer Lett 132 1998 147 152
50. M. Kempkes, K. Golka, S. Reich, T. Reckwitz, and H.M. Bolt Glutathione S-transferase GSTM1 and STT1 null genotypes as potential risk factors for urothelial cancer of the bladder Arch Toxicol 71 1996 123 126
51. A. Hirvonen, K. Pelin, L. Tammilehto, A. Karjalainen, K. Mattson, and K. Linnainmaa Inherited GSTM1 and NAT2 defects as concurrent risk modifiers in asbestos-related human malignant mesothelioma Cancer Res 55 1995 2981 2983